Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
ADHD DRUG ADDERAL XR IN CANADA

Shire’s ADHD drug Adderall back on list in Canada

Shire Pharmaceuticals drug Adderall XR to treat Attention Deficit and Hyperactivity Disorder (ADHD) gets marketing authorization in Canada.

 

BY OUR PHARMA CORRESPONDENT

31 August, 2005: The Canadian drug regulator, Health Canada has decided to reinstate the marketing authorization of Shire Pharmaceuticals drug Adderall XR to treat Attention Deficit and Hyperactivity Disorder (ADHD), in Canada effective August 26, 2005. 

This announcement follows the acceptance by Health Canada of the recommendations from the New Drug Committee (NDC), which was appointed by Health Canada at Shire’s request to review the February 9, 2005 suspension in Canada , Shire Pharmaceuticals Group plc said in a press release.

The NDC, comprised of three highly qualified, independent experts in the fields of pediatric cardiology, pediatric development and behavioral problems, and pharmacoepidemiology, examined the scientific evidence made available to them by both Shire and Health Canada.

The NDC recommendation for the reinstatement of Adderall XR in Canada, supported by both Health Canada and Shire, includes adoption of the revisions to the Canadian Product Monograph and patient leaflet that Shire previously proposed in November 2004. The NDC has also recommended that Shire distribute a Dear Healthcare Professional Letter and support independent continuing medical education for Canadian physicians to reinforce their understanding of the issues around sudden/cardiac death in the general pediatric population.

Health Canada has agreed to work with Shire to implement the recommendations of the NDC and Shire will work diligently to make Adderall XR available to Canadians in the coming weeks, the release stated.

Adderall XR was generally well tolerated in clinical studies. The most common adverse events in pediatric trials included loss of appetite, insomnia, abdominal pain, and emotional liability. The most common side effects in the adolescent trial included loss of appetite, insomnia, abdominal pain, and weight loss. The most common adverse events in the adult trial included dry mouth, loss of appetite, insomnia, headache, and weight loss. 

The effectiveness of Adderall XR for long-term use has not been systematically evaluated in controlled trials. As with other psychostimulants indicated for ADHD, there is a potential for exacerbating motor and phonic tics and Tourette's syndrome. A side effect seen with the amphetamine class is psychosis. Caution also should be exercised in patients with a history of psychosis. Abuse of amphetamines may lead to dependence. Misuse of amphetamine may cause sudden death and serious cardiovascular adverse events.

Adderall XR generally should not be used in children or adults with structural cardiac abnormalities. The drug is contraindicated in patients with symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism and glaucoma, known hypersensitivity to this class of compounds, agitated states, history of drug abuse, or current or recent use of MAO inhibitors. The drug should be prescribed with close physician supervision, the release alerted. 

Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company currently focuses on developing and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), renal diseases and human genetics. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.

BY OUR PHARMA CORRESPONDENT

Pharma News Headlines

Cancer News

Cardiac News

US FDA News

Pharma industry news

Diseases - Alzheimer's, Parkisonson's and Obesity

Contraception and Abortion News

LATEST UPDATES

Anti fungal terbinafine launched in Europe: Actavis

HIV entry blocking drug data encouraging: Progenics

Allegra generic to be launched in US

Long-acting pain drug data positive: Pain Therapeutics

New kidney cancer drug seeks EU nod

Inhaled insulin may get US FDA clearance

A vaccine against fungus is on way

Enzyme stops progression of HIV in survivors, confirms study

Aclasta found faster-acting in Paget's disease treatment

Beta blocker can start therapy in heart failure: Merck

Halobetasol generic launched in US

Anemia drug darbepoetin's late-stage studies begin: Amgen

Cholesterol generic gets marketing nod in US: Par

Aricept for severe Alzheimer’s disease too: Eisai

Bone regeneration trials begin in US:Mesoblast

New dye to detect early Alzheimer's

Breast forming gene discovered

Thyroid drug to be supplied by IVAX in US

Rituxan, cancer drug can treat rheumatoid arthritis

Yasminelle, low-dose oral contraceptive approved in the Netherlands

Fluarix, anti-flu shot by Glaxo approved

Increlex, drug to treat `abnormally short’ kids approved in US

Anti-HIV drugs prices cut: Gilead

US FDA approves Takeda’s drug combo for type 2 diabetes

Novartis’ drug for breast cancer recurrence to be given priority review in US

US puts off decision on contraceptive pill again

Shire’s ADHD drug Adderall back on list in Canada

WHO calls for emergency action to halt TB in Africa

Some of the Vioxx suits may be settled: Merck

Nasdaq delists Able on bankruptcy filing

Hospira ships ceftriaxone generics to US

Renovis stops sciatica drug studies

Merck sets up generic arm Genpharm in US

Morning after pills still not within easy reach in US

New cancer combo therapy results positive:OXiGENE

Aceon approved for heart disease treatment in US

Cell Therapeutics to seek approval for lung cancer therapy in US and Europe

Anti-depressant Seroxat defended by GSK against new findings

Vioxx verdict: Merck’s defeat to trigger thousands of lawsuits from US, UK

Aspirin stops colon cancer, but may trigger bleeding

New blood test method approved in US

Skin disease drug turns into anti-tumor therapy for cancer

Step-by-Step instructions for dealing with Asthma Attacks

Potential Alzheimer's Disease drugs under investigation

New Molecule may help obese lose weight

Paxil (Paroxetine) may heighten suicide risks, finds study

"Breast cancer chances higher due to fried chips"

Safety alert on Gambro Dasco’s Prisma renal system

Merck responsible for Vioxx death: Jury

Heart disease deaths more among New Yorkers

Pfizer to offer drugs risk/benefit summary to consumers 

Merck lied to public on Vioxx: lawyer tells jurors

Novartis acquires rights of kidney dialysis drug from SeBo

J&J's Concerta approved treatment of ADHD in teenagers in Canada

US FDA stalls Roche’ Accutane use in pregnancy

Novo Nordisk, Eli Lilly remove insulin products from Australia

British drug supply chain safety questioned after another fake Lipitor find

Wyeth starts support programme for Effexor patients

P&G’s Actonel with Calcium approved for osteoporosis

Pozen gets patent on pain management product

Genmab studies new drug for rheumatoid arthritis

Painkillers may increase blood pressure: study

Nektar buys out Aerogen for $32 m

Predix records positive data on anxiety drug

Insmed files against Increlex approval

Hepatitis A vaccine for kids approved in US

Psoriasis drug data positive: Cytochroma

Novo Nordisk’s 24-hour acting insulin Levemir gets US FDA okay

US FDA approves Teva's generic for osteoporosis 

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us